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236Another concern is that patients in the SE group
presented a signiﬁcantly higher incidence of more
than mild aortic regurgitation, a well-known predic-
tor of mortality after TAVR (5). However, the CHOICE
trial failed to show any association between aortic
regurgitation and mortality, possibly due to the
previously described imbalance in baseline
characteristics between the 2 groups.
Finally, patients in the BE group showed a trend
for an increased rate of stroke compared with SE
patients. Of interest, the authors reported an unex-
pected ﬁnding of 4 cases (3.4% of BE-implanted
patients) of early prosthetic valve dysfunction in
the BE group, possibly attributed to valve throm-
bosis, suggesting a possible link with the higher
stroke rate. However, patients enrolled in the BE
group at baseline compared with SE group also
presented a higher incidence of atrial ﬁbrillation,
despite no difference in antithrombotic therapy, that
might play a role in the higher stroke rate observed
in the BE group.*Rocco A. Montone, MD
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CHOICE Trial ResultsWe appreciate the thoughtful comments of Dr. Mon-
tone and colleagues concerning the 1-year clinical
outcome of the CHOICE trial, but do not share their
concerns about a differential impact of baseline
characteristics on the observed mortality rates in a
randomized setting. Among all baseline clinical and
echocardiographic characteristics of the CHOICE
population, only sex was statistically signiﬁcantly
different between the balloon-expandable (BE) and
self-expandable (SE) groups (age and baseline left
ventricular function were not signiﬁcantly different)
(1,2). As mentioned in the paper, we performed a
logistic regression analysis to adjust for sex, and
the results are essentially unchanged if sex is taken
into account (2) (unadjusted p value for all-cause
mortality at 1-year using the Fisher exact test ¼
0.37, adjusted p value for all-cause mortality at 1-
year using logistic regression ¼ 0.33).
The assumption of Dr. Montone et al. that more
than mild prosthetic valve regurgitation was not
associated with higher mortality in the CHOICE
population is not correct. As brieﬂy mentioned in the
discussion section of our paper (2), device success
(which was mainly driven by the absence of more
than mild paravalvular leaks) was independently
associated with improved survival at 1 year (adjusted
odds ratio calculated by logistic regression ¼ 0.16,
95% conﬁdence interval: 0.04 to 0.67, p ¼ 0.01). As
previously discussed, the lack of a mortality
difference between both devices despite differences
in device success could be partially explained by the
moderate sample size of this study as well as the
numerically higher rate of thromboembolic events in
the BE group, although this remains speculative.
Finally, a potential association between the
numerically higher incidence of baseline atrial ﬁbril-
lation (AF) and the occurrence of stroke in the BE group
cannot be entirely excluded. In fact, 6 of 11 stroke
events in the BE group occurred in patients with AF,
but the rate of new-onset AFwas nearly identical in the
BE group (9.8%) and SE group (9.4%, p ¼ 1.0) (2).*Mohamed Abdel-Wahab, MD
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Noncompaction Must
Consider Nongenetic and
Myopathic ImplicationsWe read with interest the review about isolated
left ventricular hypertrabeculation/noncompaction
(LVHT) by Hussein et al. (1). However, the paper raises
a number of concerns.
We disagree that LVHT exclusively results from
incomplete intrauterine compaction of the developing
myocardium. LVHT can be acquired in neuromuscular
disorders (NMDs) (2), in pregnant women, and in
athletes and may disappear in single cases, which
are strong arguments against the noncompaction
hypothesis.
We also disagree with the statement that LVHT
was ﬁrst described by Grant in 1926 (3). His case
does not meet current diagnostic criteria because
trabeculations were predominantly seen in the right
portion of the single ventricle because the basal
segments were predominantly affected and because
intertrabecular spaces communicatedwithmyocardial
and epicardial vessels.
Earlier than Engberding in 1984, Feldt reported in
1969 a biventricular bizarre spongy myocardial
pattern in an autopsy case and Westwood (4)
presented a ﬁgure of a case (case 3) unambiguously
showing biventricular hypertrabeculation.We also disagree with classifying LVHT as a genetic
disorder for the following reasons: LVHT has been
associated with >30 different mutated genes and
even more chromosomal defects, thus rendering it
unlikely to be responsible for the same morpho-
logical abnormality; only a limited number of muta-
tion carriers presents with LVHT (LVHT often does
not segregate with a mutation); a speciﬁc mutation
associated with LVHT in 1 family member may be
associated with variable cardiac abnormalities in
another family member; LVHT can be acquired.
Application of the LVHT mass as a cardiac magnetic
resonance imaging criterion is misleading because
this parameter does not differentiate between mass of
intertrabecular tissue (blood) and mass of trabecula-
tions (myocardium). Because the relationship be-
tween these 2 ﬁgures varies considerably between
patients, LVHT mass does not appear to be a reliable
diagnostic marker.
When considering transplantation as a treatment
of intractable heart failure, myotoxic immunosup-
pression should be avoided in patients with an NMD
to prevent further neurological deterioration.
Overall, uncertainties about diagnosis, treatment,
and prognosis of LVHT may remain unsolved as long
as the pathogenetic background of LVHT is not fully
elucidated.*Josef Finsterer, MD, PhD
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